More Stories

Informist, Friday, May 23, 2025

MUMBAI – Having ended this week in the red, Nifty Pharma is expected to reverse some losses and trade higher next week, analysts said. The sectoral index closed 0.9% down in the week-ended Friday due to profit booking and earnings misses from major players like Sun Pharmaceutical and Torrent Pharmaceuticals. Analysts are optimistic about the index's movement next week due to strong sector fundamentals.

According to India Ratings and Research, Indian pharmaceutical sector reported a growth of 7.4% year-on-year in April. This comes amid positive guidance from companies such as Dr. Reddy's and Divi's Laboratories, which are projecting double-digit growth for FY26. Analysts from domestic brokerages noted that while near-term volatility may continue due to margin pressures and regulatory concerns, the sector's defensive characteristics and export potential continue to attract investor interest.

Friday, Nifty Pharma index closed at 21,434.25 points, down 0.4%. This week, sector heavyweights, including Sun Pharmaceutical, Zydus Lifesciences, and Torrent Pharmaceuticals reported results. 

Sun Pharma reported a revenue of INR 29.09 billion for the March quarter, up 8% on year, while profit grew 11% on year to INR 4.98 billion. ICICI Securities said the company reported strong numbers for the period despite growth remaining flat in the US business. The company has guided for a mid-high single-digit revenue growth for FY26. However, it remains a preferred pick for a few domestic analysts who expressed confidence in the company's long-term fundamentals.

Mankind Pharma was the worst-performing stock on the sectoral index this week, closing down 5.5%, followed by Lupin and Sun Pharma, which fell 4.3% and 3%, respectively. IPCA Laboratories, Natco Pharma, and Gland Pharma were the top performers, rising 4.8%, 4.5%, and 4%, respectively.

TOP HEADLINES

* Alembic Pharma gets US FDA final nod for Amlodipine, Atorvastatin tablets
* Analyst Concall: Sun Pharma expects R&D spend to be 6-8% of sales FY26
* Earnings Review: Sun Pharma Jan-Mar consol PAT falls 19% YoY, misses view
* Emcure Pharma Jan-Mar consol PAT rises 64.1% on year to INR 1.89 billion
* Biocon arms' insulin supply pact with Malaysian govt extended to Oct 28
* Earnings Outlook: Domestic, US markets may aid Sun Pharma Jan-Mar PAT
* Analyst Concall: Mankind Pharma to repay acquisition-related debt by FY28
* Earnings Review:Mankind Pharma PAT beats Street but falls YoY as costs surge
* Analyst Concall:Max Healthcare to add 1,500 beds in FY26, to expand presence
* Biocon arm Biocon Biologics, Yoshindo launch Ustekinumab injection in Japan
* Earnings Review: Torrent Pharma's Jan-Mar PAT growth slowest in 7 quarters
* Earnings Outlook: Acquisition cost, weak exports to dent Mankind's PAT
* Analyst Concall:Torrent Pharma sees India business to outgrow market in FY26
* Analyst Concall: Zydus Life open to partnership, make in US on tariff threat
* Earnings Review: Max Health consol PAT growth highest in 7 qtrs, misses view
* Analyst Concall: Zydus Life open to partner, make in US amid tariff threat
* Gland Pharma Jan-Mar consol PAT falls 3.1% YoY as sales fall 7.3%
* Earnings Review:Max Health Q4 consol PAT growth highest in 7 qtrs, misses view
* Analyst Concall: PI Industries plans INR 8 bln-INR 9 bln capex in FY26
* Earnings Review: Zydus Jan-Mar consol PAT falls 1%, misses analyst estimate
* Lupin in pact with Honeywell to develop next-generation inhalers
* Cipla arm Jay Precision Pharma to acquire 26% stake in renewable energy co
* Pfizer Jan-Mar net profit rises 85% on year to INR 3.3 billion, sales up 8%
* Eris Life Jan-Mar consol PAT rises 32% on year to INR 938 million
* Earnings Outlook: India sales to help Torrent Pharma consol PAT rise 16% YoY
* Earnings Outlook: Zydus Lifesciences Jan-Mar consol PAT seen up 16% on year
* Earnings Outlook: Occupancy, specialty mix may boost Max Healthcare's Q4 PAT
* Aarti Ind gets tax notice of INR 1.63 bln; co to file rectification request
* US FDA tags Cipla arm's Navi Mumbai unit as 'voluntary action indicated'
* Analyst Concall: Divi's Labs expects revenue to grow in double digit in FY26
* Dr Reddy's gets 2 observations from US FDA for New York unit
* Max Healthcare arm buys land parcel for capacity addition in Uttar Pradesh
* Sun Pharma gets US FDA nod for new blue light therapy illuminator device
* GSK Pharma reports fire incident at contract manufacturing facility
* Jubilant Pharmova posts INR-1.54-bln consol PAT in Jan-Mar vs loss year ago

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by P Madhu Kumar

Edited by Deepshikha Bhardwaj

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.